About Us

We are a clinical-stage biotechnology company with a proprietary and differentiated Rational Antibody Discovery (RAD) platform, developing a broad pipeline of novel, precision therapeutics for the treatment of cancer and autoimmune disease.

We are focused on targets with significant biological validation and disease association that have not been drugged, or are inadequately drugged to date, which we refer to as “hard targets”.


Piers Ingram, PhD, MBA
Chief Executive Officer, Co-Founder, Executive Director

Jerome Boyd-Kirkup, PhD
Chief Scientific Officer, Co-Founder


Eric Rowinsky, MD
Chief Medical Officer

Konrad Paszkiewicz, PhD
Chief Technology Officer

Joshua House
Chief Financial Officer

Leah DiMascio, PhD
Chief Development Officer

Dipti Thakkar, PhD
VP-Target Biology & Pharmacology

Brendon Hanson, PhD
VP-Discovery and Research Platforms

Namita Gandhi, PhD
VP-Disease Area Strategy

Annie Lim
VP-Human Resources

Lisa Ooi, PhD

Iris Tan

Gary Khoo, PhD

Kwek Kon Yew, BM BCh, DPhil
VP-Clinical Development

Haibo Wang
VP-Business Development

Jan Møller Mikkelsen

Dan Estes, PhD
Non-Executive Director

Kenneth Harrison, PhD
Non-Executive Director

Kiel Kim, MBA
Non-Executive Director

Thomas Lynch, MD
Non-Executive Director

Victor E. Tong
Non-Executive Director

Piers Jamie Ingram, PhD, MBA
Executive Director

James P. Allison, PhD
2018 Nobel Laureate in Medicine

Padmanee Sharma, PhD, MD
Professor of Medical Oncology, The University of Texas MD Anderson Cancer Center

John Connolly, PhD
Chief Scientific Officer of The Parker Institute for Cancer Immunotherapy

Jianzhu Chen, PhD
Professor of Biology at Koch Institute for Integrative Cancer Research, MIT


Wee Joo Chng, MB ChB, PhD

Yong Loo Lin Professor in Medical Oncology and Vice Dean, Research
at Yong Loo Lin School of Medicine, National University of Singapore
Director and Senior Consultant at National University Cancer Institute, Singapore, National University Health System

Together we aim to accelerate the journey of new drugs from concept to clinical care.